# Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

> **NCT00383786** · PHASE2 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 47 (actual)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** NK1 Antagoist (GR205171)
- **PROCEDURE:** Psychophysiology (Trauma Script)
- **PROCEDURE:** Psychophysiology (Verbal Threat)
- **PROCEDURE:** Psychophysiology (Fear Conditioning)
- **PROCEDURE:** Psychophysiology (Affective Modulation)
- **PROCEDURE:** Psychophysiology (Heart rate variability)
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** 24-hour plasma sampling
- **PROCEDURE:** MRI

## Key facts

- **NCT ID:** NCT00383786
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383786, "Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00383786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*